The STAT guide to viral vectors, the linchpin of gene therapyIndividual

We dive into the science, and business, behind viral vectors. We spoke with executives from 18 companies to identify the pipeline of therapies that are nearing the clinic, the engineering and production challenges that may stifle progress, and how key players are looking to overcome those challenges. Learn more.

Read the full article here

Related Articles